HighVista Strategies’s Terns Pharmaceuticals TERN Stock Holding History

HighVista Strategies’s Portfolio TERN Stock Details TERN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6.03M	Sell	114,307 -61,155	-35%	-$2.51M	1.66%	8
2025 Q4	$7.09M	Buy	+175,462	New	+$4.05M	1.83%	10
2025 Q1	–	Sell	-130,966	Closed	-$726K	–	163
2024 Q4	$726K	Hold	130,966	–	–	0.27%	114
2024 Q3	$1.09M	Sell	130,966 -17,234	-12%	-$142K	0.38%	98
2024 Q2	$1.01M	Hold	148,200	–	–	0.37%	101
2024 Q1	$972K	Hold	148,200	–	–	0.35%	97
2023 Q4	$962K	Hold	148,200	–	–	0.35%	89
2023 Q3	$745K	Sell	148,200 -31,470	-18%	-$200K	0.35%	70
2023 Q2	$1.57M	Buy	179,670 +32,816	+22%	+$382K	0.72%	40
2023 Q1	$1.74M	Buy	146,854 +69,510	+90%	+$664K	1.42%	26
2022 Q4	$787K	Hold	77,344	–	–	0.47%	64
2022 Q3	$456K	Buy	+77,344	New	+$287K	0.26%	84

Other funds holding TERN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

HighVista Strategies's TERN Position: Q1 2026 in Review

HighVista Strategies reduced its Terns Pharmaceuticals (TERN) stake by 35% in Q1 2026, selling an estimated $2.51M and leaving 114,307 shares worth $6.03M. The position accounts for 1.66% of the portfolio, ranked #8.

HighVista Strategies first reported a position in TERN in Q3 2022 and has held it in 12 quarters since. The position peaked at $7.09M in Q4 2025. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

HighVista Strategies held 114,307 shares of Terns Pharmaceuticals worth $6.03M as of Q1 2026.
HighVista Strategies sold 61,155 Terns Pharmaceuticals shares in Q1 2026, an estimated $2.51M.
Terns Pharmaceuticals made up 1.66% of HighVista Strategies's portfolio in Q1 2026, its #8 holding.
HighVista Strategies first reported a position in Terns Pharmaceuticals in Q3 2022 and has held it in 12 quarters since.
HighVista Strategies's Terns Pharmaceuticals position peaked at $7.09M in Q4 2025.
317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on HighVista Strategies's 13F filing for Q1 2026, filed 15 May 2026.